Investor Update Agenda

RNS Number : 6976O

Scancell Holdings Plc

24 September 2013

 



Scancell Holdings Plc

('Scancell')

Investor Update Agenda

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013.  Details of the event are:

Location	FTI Consulting Holborn Gate 26 Southampton Buildings London, WC2A 1PB
10.45	Registration with refreshments
11.00	Introduction David Evans, Scancell Non-Executive Chairman
11.05	Cancer immunotherapy Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester
11.20	Scancell corporate update Dr Richard Goodfellow, Joint CEO of Scancell
11.30	SCIB1 trial update and introduction to Moditope™ Prof Lindy Durrant, Joint CEO of Scancell
11.45	Q&A
12.00	Interactive panel discussion Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital Panellists include: Prof Lindy Durrant, Prof Peter Stern, Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton
12.45	Buffet lunch
13.30	Close

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc Scancell Holdings Plc	+ 44 (0) 20 7831 3113
Camilla Hume/Stephen Keys	Cenkos Securities	+ 44 (0) 20 7397 8900
Mo Noonan/Eleanor Clarke	FTI Consulting	+ 44 (0) 20 7831 3113

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

NRADXLFLXKFLBBB